Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Active-Controlled, Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of 0.08% PHMB Ophthalmic Solution in Comparison With 0.02% PHMB + 0.1% Propamidine Combination Therapy in Subjects Affected by Acanthamoeba Keratitis

NCT03274895 is registered in ClinicalTrials.gov with SIFI SpA as lead sponsor.

NCT NCT03274895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03274895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Active-Controlled, Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of 0.08% PHMB Ophthalmic Solution in Comparison With 0.02% PHMB + 0.1% Propamidine Combination Therapy in Subjects Affected by Acanthamoeba Keratitis
Lead sponsor
SIFI SpA
Phase
Phase 3
Overall status
Completed
Start date
August 13, 2017
Completion date
March 30, 2022
Enrollment
135 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acanthamoeba keratitis